, PPV
, Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group, Br J Haematol, vol.121, pp.749-57, 2003.
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma, Blood, vol.111, pp.785-794, 2008. ,
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, Leukemia, vol.23, pp.215-239, 2009. ,
Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma, Leukemia, vol.27, pp.941-947, 2013. ,
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria, Blood Cancer J, vol.8, p.59, 2018. ,
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, pp.1692-700, 2011. ,
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, N Engl J Med, vol.356, pp.2582-90, 2007. ,
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, pp.1625-1659, 2002. ,
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma, Blood Cancer J, vol.6, p.454, 2016. ,
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression, Leukemia, vol.32, pp.1427-1461, 2018. ,
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-586, 2014. ,
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling, Blood Adv, vol.2, pp.1470-1479, 2018. ,
Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine, Clin Chem, vol.47, pp.673-80, 2001. ,
N Latex FLC -new monoclonal high-performance assays for the determination of free light chain kappa and lambda, Clin Chem Lab Med, vol.49, pp.1323-1355, 2011. ,
Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum ? and ? immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool, Clin Chem Lab Med, vol.55, pp.424-458, 2017. ,
Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods, Clin Chem Lab Med, vol.56, pp.312-334, 2018. ,
Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis, Clin Chem Lab Med, vol.50, pp.489-95, 2012. ,
Polyclonal versus monoclonal immunoglobulin-free light chains quantification, Ann Clin Biochem, vol.52, pp.327-363, 2015. ,
Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy, BMC Clin Pathol, vol.12, p.12, 2012. ,
Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents, Clin Chem Lab Med, vol.54, pp.997-1003, 2016. ,
Evaluation of the impact of renal failure on correlation and concordance between 2 free light chain assays, Clin Lymphoma Myeloma Leuk, vol.16, pp.693-704, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01427008
Analytical criticalities associated to different immunological methods for serum free light chain detection in plasma cell dyscrasias: a description of particular clinical cases, Int J Mol Sci, vol.18, p.804, 2017. ,
Performance evaluation of serum free light chain analysis: nephelometry vs. turbidimetry, monoclonal vs. polyclonal reagents, Am J Clin Pathol, vol.147, pp.611-633, 2017. ,
Diagnosis of smoldering multiple myeloma, N Engl J Med, vol.365, pp.474-479, 2011. ,
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma, Blood Cancer J, vol.8, p.107, 2018. ,
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma, Blood Adv, vol.2, pp.3149-54, 2018. ,
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease, Leukemia, vol.27, pp.947-53, 2013. ,
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study, Eur J Haematol, vol.97, pp.303-312, 2016. ,
Smoldering Multiple Myeloma: Who and When to Treat, Clin Lymphoma Myeloma Leuk, vol.17, pp.716-738, 2017. ,
Timing of treatment of smoldering myeloma: delay until progression, Blood Adv, vol.2, pp.3050-3053, 2018. ,
Timing of treatment of smoldering myeloma: early treatment, Blood Adv, vol.2, pp.3045-3054, 2018. ,